Background: Although acute exacerbations, mostly triggered by viruses, account for the majority of hospitalizations in asthmatic patients, there is still very little known about the pathophysiologic mechanisms involved. Plasmacytoid dendritic cells (pDCs), prominent cells of antiviral immunity, exhibit proinflammatory or tolerogenic functions depending on the context, yet their involvement in asthma exacerbations remains unexplored.
Objectives: We sought to investigate the role of pDCs in allergic airway inflammation and acute asthma exacerbations. Methods: Animal models of allergic airway disease (AAD) and virus-induced AAD exacerbations were used to dissect pDC function in vivo and unwind the potential mechanisms involved. Sputum from asthmatic patients with stable disease or acute exacerbations was further studied to determine the presence of pDCs and correlation with inflammation. heightened during exacerbations and correlate with the severity of asthma attacks 4, 14, 15 has been puzzling. Although epitheliumderived cytokines, such as IL-25 and IL-33, triggered by viral infections can boost T H 2 responses during exacerbations, [15] [16] [17] the underlying mechanisms involved remain poorly defined.
Plasmacytoid dendritic cells (pDCs) are rare but functionally important bone marrow-derived cells that circulate in the blood and home to secondary lymphoid organs and sites of inflammation. Although they share functional properties with conventional dendritic cells, major drivers of T H 2 cell responses in the respiratory track, 18 including MHC class II and costimulatory molecule expression, migratory capacity, and antigen-presenting function, they constitute a dendritic cell subclass on their own because of their plasmacytoid appearance, relatively low antigen-processing capacity, and unique ability to secrete type I interferons. 19, 20 pDCs are prominent in antiviral immunity. 21, 22 They can also stimulate CD4
1 and CD8 1 T-cell activation and even engage in naive T-cell priming and initiation of adaptive immunity. 23 Conversely, pDCs can mediate peripheral and central tolerance by inducing forkhead box protein 3-positive regulatory T cells, preventing allograft rejection and autoimmunity. 24, 25 This has resulted in discussion over their ''immunogenic'' versus ''tolerogenic'' functions, which is now attributed to their notable plasticity in different microenvironments. Although immature pDCs appear to drive ''by default'' tolerogenic/immunoregulatory processes, in inflammatory contexts pDCs can promote proinflammatory responses.
In asthmatic patients pDCs have not been explored sufficiently. Although they are present in the sputum and bronchoalveolar lavage (BAL) fluid of patients with stable disease and can be increased on allergen provocation, [26] [27] [28] their functional relevance to the disease process has not been addressed. Moreover, although they have been shown to prevent induction of allergic sensitization and consequent development of subsequent inflammation in animal models of allergic airway disease (AAD) [29] [30] [31] because their depletion under homeostasis results in increased T-cell priming, this is not informative about their role in the context of established disease. Thus it is not known how pDCs function in the allergic inflammatory environment that characterizes human asthma. Most importantly, it is not known how pDCs function during disease exacerbations in either human or animal model settings, leaving a large gap of knowledge about their function in asthma pathophysiology.
Here we used experimental animal models to investigate the role of pDCs in established AAD and rhinovirus-induced exacerbations of AAD, and dissect the cellular and molecular mechanisms involved. We have characterized their presence in the persistence and exacerbations of T H 2 responses, their functional importance after pDC depletion, and their involvement in IL-25-mediated proinflammatory effects. Furthermore, we have studied asthmatic patients during stable disease or acute exacerbations to determine the presence of pDCs in their sputum and identify disease-relevant associations. Our findings propose a central disease-exacerbating role of pDCs in AAD and asthma, and challenge the prevailing concept in the field that pDCs are broadly protective.
METHODS
Mouse models, treatments, and readouts AAD was induced in C57BL/6 mice that were sensitized and challenged with ovalbumin (OVA), as previously described. 32 Rhinovirus exacerbation of AAD was induced in BALB/c mice sensitized and challenged with OVA and exposed intranasally to 1 3 10 7 median tissue culture infective dose of rhinovirus 1B or saline, as reported previously. 33 For pDC depletion, mice were treated intraperitoneally with 250 mg per mouse of 120G8 anti-mouse antibody (Dendritics, Lyon, France) or controls, as indicated in the experimental protocol. For IL-25 treatment, mice were administered intranasally 1 mg of recombinant IL-25 (BioLegend, San Diego, Calif) per mouse or PBS, as specified. For IL-25 neutralization, mice were treated intraperitoneally with 500 mg of anti-mouse IL-25 (clone DDG91; Janssen Pharmaceuticals, Raritan, NJ) per mouse or isotype control. Mice were killed at various time points for end point analyses, as detailed in the Methods section in this article's Online Repository at www.jacionline.org.
Human subjects, sputum induction, and analysis Study subjects were recruited from an open cohort of patients who were followed up for at least 2 years. In total, 34 participants with an age range of 34 to 79 years were enrolled: 6 healthy subjects, 13 patients with moderate-to-severe asthma in stable condition, and 13 patients with exacerbations within 48 hours of manifestation of symptoms. Sputum was induced by means of inhalation of hypertonic saline aerosol and processed by using standard methodologies. 34 Leukocyte fractions were subjected to immediate flow cytometric analysis, whereas supernatants were kept at 2708C for subsequent measurements, as detailed in the Methods section in this article's Online Repository.
RESULTS pDC numbers are increased in the lungs and mediastinal lymph nodes of mice with AAD
We first used an established mouse model of AAD based on systemic OVA sensitization and subsequent OVA aerosol challenge (Fig 1, A) to characterize the spatiotemporal presence of pDCs in the lungs and lung draining mediastinal lymph nodes (MLNs) during the development of inflammation. Inflammation in this model peaks at day 1 after challenge and decreases thereafter (see Fig E1, A-E, in this article's Online Repository at www.jacionline.org), as previously reported. 35 Using anti-plasmacytoid dendritic cell antigen 1 (PDCA-1) staining of lung sections and immunofluorescence microscopy, we observed that pDCs were scarce during homeostasis and mainly located in the parenchyma (Fig 1, B) . However, at day 1 after challenge, the peak of the inflammatory response, pDC numbers increased markedly, especially in peribronchial and perivascular infiltrates around the airways and clusters in the parenchyma (Fig 1, C) . We also used flow cytometry to quantify the presence of pDCs in the lungs and MLNs of naive, OVA-sensitized, and OVA-challenged mice over a period of 11 days. We found that increased pDC numbers, identified as CD45
B220
1 sialic acid-binding immunoglobulin type lectin H (Siglec-H) 1 cells (see Fig E1, F) , infiltrated the lung at day 1 after challenge and gradually decreased thereafter (Fig 1, D) . Increased numbers of pDC also infiltrated MLNs, peaking at day 4 after challenge (Fig 1, E) . These data indicate that pDCs infiltrate the lung and migrate to the MLNs during development of allergic airway inflammation, and might therefore be involved in the disease process.
pDCs promote allergic inflammatory responses in the airways during established experimental asthma
To examine whether pDCs can functionally affect established AAD and modulate inflammation severity or persistence, we used 120G8, a widely used pDC-depleting antibody binding to A, Experimental protocol of allergic airway inflammation. C57BL/6 mice were sensitized with OVA-alum and challenged with aerosolized OVA. Tissue collection was performed at the indicated time points. i.p., Intraperitoneal. B and C, Immunofluorescence staining of 120G8 1 pDCs in the lung during homeostasis (Fig 1, B) or inflammation at day 1 after challenge (Fig 1, C) . DAPI, 49-6-Diamidino-2-phenylindole dihydrochloride. D and E, Representative flow plots and graphs of CD45
Siglec-H 1 pDCs from whole-lung digests (Fig 1, D) and MLNs (Fig 1, E) of naive, OVA-sensitized, and OVA-sensitized and challenged mice at the indicated time points throughout resolution. Means 6 SEMs of 5 mice per group from one representative of 2 independent experiments are shown. *P < .05 and **P < .01. (Fig 2, B) and quantification of pDC depletion until day 11 after challenge (Fig 2, C) . D and E, Total leukocyte (Fig 2, D) and eosinophil (Fig 2, E) counts in BAL fluid of 120G8-treated mice at the indicated time points. Leukocyte numbers in healthy control subjects or saline-challenged animals were 5 3 10 4 cells or less. F and G, Histologic assessment of lung inflammation in 120G8-, isotype-, or PBS-treated mice at days 4 and 7 after challenge. Hematoxylin and eosin-stained sections (Fig 2, F) and histologic scores (Fig 2, G) are shown. H, OVA-specific IL-5 and IL-13 production in supernatants of OVA-stimulated MLN cultures at day 4 after challenge. I, Airway hyperreactivity at day 2 after OVA challenge. Healthy control (CTL) mice were challenged with saline. MCh, Methacholine. Data are expressed as percentage increase from baseline of total lung resistance. Means 6 SEMs of 4 (Fig 2, C) , 14 to 20 (Fig 2, D and E), 6 to 8 (Fig 2, G and I) , or 8 to 14 (Fig 2, H) mice per group from 2 to 3 independent experiments are shown. *P < .05, **P < .01, and ***P < .001. B, Representative dot plots and percentages of total pDCs from one of 2 independent experiments are shown. C, Histogram plots and mean fluorescence intensity (MFI) of OX40L and CD40 expression of MLN pDCs at day 1 after challenge. One representative from 3 independent experiments is shown. D, Cytokine production of IL-5, IL-10, and IL-13 in supernatants of medium-or OVA-stimulated pDC-depleted MLN cultures. Means 6 SEMs of 6 to 14 mice per group from 2 independent experiments are shown. *P < .05, **P < .01, and ***P < .001. (Fig 4, C) and differential cell counts for eosinophils (EOS), monocytes/macrophages (MON), neutrophils (NEU), and lymphocytes (LYMPH ; Fig 4, D) in BAL fluid at day 1 after rhinovirus infection. Leukocyte numbers in healthy control or saline-challenged animals were 5 3 10 4 cells or less. E, Histologic assessment of lung inflammation at day 1 after rhinovirus infection. Hematoxylin and eosin-stained sections and histologic scores are shown. F, Airway hyperreactivity of 120G8-or I.C.-treated mice at day 1 after rhinovirus infection. Percentage increase from baseline of total lung resistance is shown. MCh, Methacholine. G, OVA-specific IL-5, IL-10, IL-13, and IFN-g production in supernatants of OVA-stimulated MLN cultures at day 1 after rhinovirus infection. Means 6 SEMs of 7 to 12 mice per group from 2 to 3 independent experiments are shown. *P < .05, **P < .01, and ***P < .001. , and 5 to 6 (Fig 5, F and G) mice per group from 2 to 3 independent experiments are shown. *P < .05, **P < .01, and ***P < .001.
PDCA-1 (see Fig E2, A and B, in this article's Online Repository at www.jacionline.org). 36 We observed that repeated intraperitoneal injections of 120G8 at days 1, 3, and 5 after challenge depleted pDC numbers in the lung by 65% at day 4 and 50% by days 7 and 11 compared with vehicle (PBS), whereas isotype control antibody had no effect (Fig 2, A-C) . 120G8 effectively depleted pDCs in MLNs as well (see Fig E2, C) . Notably, pDC depletion profoundly affected disease. It rapidly reduced total leukocyte numbers in BAL fluid (Fig 2, D) , especially eosinophils (Fig 2, E) and T cells (see Fig E2, D-F) . It also decreased peribronchial and perivascular inflammatory cell infiltrates in the lungs and OVA-specific T H 2 responses in MLNs (Fig 2, F and G) without affecting IL-10 or IL-17, whereas IFN-g was upregulated (Fig 2, H , and see Fig E2, G) . In this setting type I interferons were not induced (see Fig E2, H) . Airway hyperreactivity measured as a methacholine-induced increase in total lung resistance was also decreased in 120G8-treated mice (Fig 2, I) .
On the contrary, administration of 120G8 before OVA challenge had the opposite effect. It increased total leukocyte and eosinophil counts in BAL fluid, inflammatory cell infiltration in the lungs, and T H 2 cell responses in MLNs, aggravating overall inflammation and pathology (see Fig E3 in this article's Online Repository at www.jacionline.org). This was in accordance with previous studies 30, 31 indicating profound functional differences of pDCs found in a ''homeostatic'' versus ''inflammatory'' environment. Therefore pDCs promote allergic inflammatory responses in the lung once disease has been established.
Activated pDCs carrying allergen reach the MLNs and boost T H 2-mediated allergic responses
To understand how pDCs exert their proinflammatory effects in patients with AAD, we challenged mice intranasally with labeled OVA (OVA-fluorescein isothiocyanate [FITC] ) and examined pDC migration and function in MLNs (Fig 3, A) . We observed that up to 20% of MLN pDCs at day 1 after challenge were OVA-FITC
1
, and among them, a fifth expressed the chemokine receptor CCR7, which is key for cell trafficking to MLNs (Fig 3, B) . We also observed that pDCs from OVA-challenged mice expressed higher levels of CD40 and OX40 ligand (OX40L) than those from PBS-challenged mice (Fig 3, C) , whereas CD80 and CD86 levels were not altered (see Fig E4, A, in this article's Online Repository at www.jacionline.org). Because CD40 and OX40L are key activation markers involved in T-cell priming, these data indicated that activated pDCs carrying antigen reach the MLNs. Subsequently, we investigated whether pDCs in MLNs could affect directly effector T H 2 responses to OVA. We used MLN cultures of OVA-challenged mice depleted from pDCs by using cell sorting (see Fig E4, B) or magnetic beads (see Fig E4, C and D) and found that MLNs that lacked pDCs had a profoundly impaired ability to produce IL-5, IL-10, and IL-13 in response to OVA (Fig 3, D) , demonstrating that pDCs promote T H 2 responses and contribute to airway pathology by becoming activated and migrating to the MLNs.
pDCs infiltrate the lungs of mice during rhinovirusinduced exacerbations of experimental asthma and drive disease
We next investigated whether pDCs are also important during viral exacerbations. We used a mouse model of rhinovirusinduced exacerbations of AAD (Fig 4, A) , which leads to rapid increases in inflammatory cells, including eosinophils and neutrophils in BAL fluid and OVA-specific T H 2 responses in MLNs, within 24 hours of infection (see Fig E5, A-C, in this article's Online Repository at www.jacionline.org). 33 In this setting we observed that pDC numbers were further increased beyond the levels of OVA-challenged mice by 50% to 55% in both the lungs and MLNs at day 1 after infection (Fig 4, B , and see Fig E5, D) . Therefore we studied whether pDCs could also play a functional role in rhinovirus-induced exacerbations of AAD by administering 120G8 1 day before and during rhinovirus challenge to ensure that pDCs are diminished at the time of viral infection (see Fig E5, E and F) .
We found that pDC depletion completely abrogated rhinovirusinduced exacerbation of experimental asthma. It suppressed inflammatory cell infiltration in BAL fluid and diminished eosinophil, neutrophil, and lymphocyte numbers (Fig 4, C and  D) . It also decreased leukocyte infiltration in the lung (Fig 4, E) and abrogated rhinovirus-induced airway hyperreactivity (Fig 4,  F) . Notably, production of IL-5, IL-10, IL-13, and IL-17 in MLNs was reduced, whereas IFN-g was upregulated (Fig 4, G , and see Fig E5, G) . In the BAL fluid IFN-a was induced on rhinovirus infection and downregulated after pDC depletion, whereas IFN-b was not detectable (see Fig E5, H) . Interestingly, pDC depletion downregulated inflammation in OVA-challenged control mice that received saline (Fig 4, C-E) , demonstrating in a different setting and genetic background of established AAD that these cells exhibit a proinflammatory function. Therefore these data highlight the central detrimental role of pDCs in promoting rhinovirus-mediated exacerbation of AAD.
IL-25 acts on pDCs to trigger their accumulation and proinflammatory activation in the lung
To characterize the molecular link or links between allergen challenge, viral infections, and pDC-triggered inflammation, we hypothesized that epithelium-derived cytokines, such as IL-25, IL-33, and/or thymic stromal lymphopoietin (TSLP), could be involved critically. We first studied their presence in BAL fluid and observed that although IL-33 and TSLP were barely detectable during either established AAD or rhinovirus-induced exacerbation models, IL-25 was induced robustly (Fig 5, A and  B) . We also examined expression of their receptors and found that IL-17RA and IL-17RB, the 2 components of the IL-25 receptor, were expressed at the mRNA level in both bone marrow-derived pDCs (Fig 5, C) and MLN-sorted pDCs (see Fig E4, B, and E6, A, in this article's Online Repository at www.jacionline.org), as was IL-7RA, the TSLP receptor's second chain. In contrast, IL-1RL/ST2, the receptor for IL-33, and cytokine receptor-like factor 2 (CRLF2), the unique chain of the TSLP receptor, were virtually absent, suggesting that pDCs preferentially respond to IL-25. However, this does not exclude a role for TSLP or even IL-33 in this process because CRLF2 can be upregulated on Toll-like receptor (TLR) activation as well. 37 Therefore we investigated whether IL-25 could affect pDC function. We noticed that although rIL-25 by itself did not exert profound effects in pDCs in culture and did not induce their proliferation, it synergized with oligodeoxynucleotide (ODN; TLR9) and R-848 (TLR7) stimulation to upregulate proinflammatory cytokines and costimulatory molecules, such as IL-6, A, OVA-challenged C57BL/6 mice were treated Intraperitoneally (i.p.) with anti-IL-25 mAb (aIL-25), isotype control (I.C.), or vehicle (PBS) and analyzed at day 4 after challenge. B, Quantification of pDC depletion in lungs and MLNs. C and D, Total leukocyte (Fig 6, C) and eosinophil (Fig 6, D) numbers in BAL fluid of anti-IL-25-, I.C.-, or PBS-treated mice. E, Histologic assessment of lung inflammation. Hematoxylin and eosin-stained sections and histologic scores are shown. F, IL-5, IL-10, and IL-13 production in supernatants of OVA-stimulated MLN cultures. Means 6 SEMs of 6 to 8 mice per group from 2 independent experiments are shown. *P < .05, **P < .01, and ***P < .001. (Fig 7, C) and eosinophil (Fig 7, D) numbers in BAL fluid of anti-IL-25-or I.C.-treated mice. E, Histologic assessment of lung inflammation. Hematoxylin and eosin-stained sections and histologic scores are shown. F, IL-5, IL-10, and IL-13 production in supernatants of OVA-stimulated MLN cultures. G, Airway hyperreactivity of anti-IL-25-or I.C.-treated mice at day 1 after rhinovirus infection expressed as a percentage increase from baseline of total lung resistance. MCh, Methacholine. Statistical significance of anti-IL-25-versus I.C.-treated mice is shown. Means 6 SEMs of 6 to 8 mice per group from 2 independent experiments are shown. *P < .05, **P < .01, and ***P < .001.
TNF, IFN-b, and CD40 (Fig 5, D) . Because IL-6 plays a major role in the development of T H 2 over T H 1 responses 38, 39 and because CD40 is a critical determinant of optimal T-cell activation, 40 these data suggest a mechanism by which IL-25 can promote pDC-mediated allergic responses in the airways. Accordingly, we observed that single or repeated intranasal administration of rIL-25 to experimental animals after challenge (see Fig E6, B) doubled pDC numbers in the lungs and MLNs (Fig 5, E, and see Fig E6, C) . At the same time, rIL-25 treatment augmented total leukocyte and eosinophil numbers in the BAL fluid (Fig 5, F and G) and inflammatory cell infiltrates in the lung by greater than 50% at day 4 after challenge (Fig 5, H) and increased IL-13 production (see Fig E6, D) . These findings demonstrate that IL-25 directly controls pDC activation and suggest a mechanism through which allergens and viruses can modulate pDC-mediated proinflammatory function. and CD45 1 leukocytes in sputum of asthmatic patients during stable disease and exacerbations. SS, Side scatter. B, Total pDC numbers in the sputum of healthy subjects and asthmatic patients during stable disease or exacerbations analyzed by using flow cytometry. C, Total CD45 1 leukocyte numbers in sputum of healthy subjects and asthmatic patients during stable disease or exacerbations analyzed by using flow cytometry. D, Total pDC numbers in the sputum of the same patient during stable disease or exacerbation. E, Correlation of pDC numbers with eosinophils, neutrophils, and T lymphocytes in sputum of asthmatic patients during exacerbations. F, Pearson or Spearman correlation coefficient of pDC numbers with inflammatory cytokines and chemokines in the sputum supernatants of asthmatic patients during exacerbations. Statistically significant correlations are highlighted in red. G, Total pDC numbers in patients with stable asthma with less than 2 and 2 or more exacerbations per year. Statistical analysis for Fig 8, B , C, and F, was conducted nu using the Kruskal-Wallis test with Dunn multiple comparison post hoc analysis. *P < .05, **P < .01, and ***P < .001.
IL-25 neutralization reduces pDC accumulation in the lung and suppresses AAD
Because our findings pointed to a key role of IL-25 in pDCmediated aggravation of allergic airway inflammation, we investigated whether targeting endogenous IL-25 can prevent pDC accumulation and proinflammatory function in patients with AAD. We found that repeated intraperitoneal administration of DDG91, a potent anti-IL-25 neutralizing antibody, 41 after challenge (Fig 6, A) decreased the presence of pDCs in the lungs and MLNs (Fig 6, B) and reduced total leukocyte and eosinophil numbers in BAL fluid (Fig 6, C  and D) without affecting the presence of macrophages and neutrophils (see Fig E7, A-C, in this article's Online Repository at www.jacionline.org). Moreover, anti-IL-25 treatment diminished inflammatory cell infiltration in peribronchial and perivascular areas of the lung (Fig 6, E) and suppressed OVA-specific IL-5, IL-10, and IL-13 production in MLNs (Fig 6, F) . These observations support a central role of endogenous IL-25 in activation and migration of pDCs to the lung and induction of AAD.
IL-25 neutralization reduces pDC infiltration in the lung and suppresses rhinovirus-induced exacerbation of experimental asthma
Subsequently, we examined the effect of IL-25 targeting in migration of pDCs to the lung and exacerbation of AAD on rhinovirus infection. We found that administration of DDG91 at the time of viral infection (Fig 7, A) prevented pDC accumulation in the lungs and MLNs (Fig 7, B) and suppressed rhinovirus-induced exacerbation of allergic airway inflammation by reducing leukocyte infiltration in BAL fluid and lung tissue (Fig 7, C-E , and see Fig E7, D-F) and production of T H 2 cytokines in MLNs (Fig 7, F) . Interestingly, IFN-g production was not affected (see Fig E7, G) , indicating the existence of an IL-25-independent pathway in its regulation. Administration of DDG91 also suppressed airway hyperreactivity measured as methacholine-induced increases in total lung resistance in Fig 7, G. Taken together, these data favor a causal effect of IL-25-regulated pDC function and exacerbation of allergic airway responses after rhinovirus infection.
pDC numbers are increased in the sputum of patients during asthma exacerbations and correlate with the severity of inflammation and disease Finally, we sought to investigate whether pDCs are also important in acute exacerbations of asthma in human subjects. Initially, we assessed the presence of pDCs in sputum from 6 healthy subjects, 13 asthmatic patients with stable disease, and 13 asthmatic patients within 48 hours of first symptoms of exacerbation and before any new treatment (see Table E1 in this article's Online Repository at www.jacionline.org). Multicolor flow cytometry was used to monitor pDCs, which were identified as CD45 
CD123
1 blood dendritic cell antigen 2 (BDCA-2) 1 cells, as well as various other immune cell populations (Fig 8, A) . We found that although pDCs were present in all asthmatic patients, they were markedly upregulated (up to 4-fold) in patients during acute exacerbations (Fig 8, B) . By comparison, pDCs were detectable in only 2 of the 6 healthy subjects examined and still at very low numbers. These significant differences in pDC numbers between the groups were not paralleled by similar increases in total leukocyte presence because higher counts during acute exacerbations were not statistically significant (Fig 8, C) . Notably, in the same patient sputum pDC numbers were markedly increased during exacerbation compared with those in patients with stable disease (Fig 8,  D) , indicating that pDC monitoring constitutes a better approach for distinguishing between these different situations. pDCs from asthmatic patients exhibited an activated phenotype, expressing higher levels of CD80, CD86, and programmed death ligand 1 in both groups compared with pDCs from the 2 healthy subjects (see Fig E8, A, in this article's Online Repository at www.jacionline.org). Increased pDC numbers were associated with higher total CD45 1 leukocyte, eosinophil, neutrophil, and T-lymphocyte counts during exacerbations but not with stable disease (Fig 8, E , and see Fig E8, B and C) , and higher levels of inflammatory mediators, such as IL-5, IL-6, IL-8, IFN-g, GM-CSF, CCL-2 (monocyte chemoattractant protein 1), CCL3 (macrophage inflammatory protein 1a), and CCL4 (macrophage inflammatory protein 1b; Fig 8, F , and see Fig E8, D) . Moreover, increased pDC numbers were found in frequent exacerbators (ie, patients with > _2 exacerbations per year) compared with patients who exhibit exacerbations less often (Fig 8, G) . These data demonstrate that high pDC numbers are related to a higher risk for exacerbations during stable disease and more pronounced inflammatory responses during disease exacerbations.
DISCUSSION
Our study uncovered a new role for pDCs in asthma exacerbations. It revealed that pDCs are highly upregulated in the sputum of patients with acute exacerbations and correlate with the intensity of asthmatic inflammation and the frequency of asthma attacks. Moreover, it demonstrates that pDCs are critical in driving allergic airway responses in animal models of established AAD and rhinovirus-induced AAD exacerbations. Thus our study positions pDCs at the center of the immunopathogenic process that mediates asthmatic inflammation, sheds light on previously unsuspected aspects of their biology in allergic responses, and proposes new potential methods for the diagnosis, prognosis, and treatment of acute asthma exacerbations.
Central to the proasthmatic effects of pDCs is their role in type 2 inflammation. pDCs are well established inducers of T H 1 and cytotoxic T-cell differentiation, especially in the context of viral infections and autoimmunity. However, despite early seminal studies using human cells describing the ability of pDCs to promote T H 2 differentiation in culture, [42] [43] [44] their involvement in T H 2 responses in vivo, especially in the context of allergic disease, has remained largely unexplored. Thus our work fills in this gap by providing ample evidence that pDCs are potent inducers of T H 2-mediated allergic responses in the lung, driving the persistence of AAD and its exacerbations. In patients higher pDC numbers are directly linked to increased numbers of eosinophils, neutrophils, T lymphocytes, and proinflammatory cytokine networks in sputum during exacerbations but not during stable disease. These findings highlight the key role of pDCs in T H 2-driven allergic responses in the airways, with important therapeutic implications.
Our study provides insight into the mechanism of action of pDCs. It shows that in the context of established disease, pDCs are activated, take up inhaled allergen, and migrate to the MLNs to support activation of effector T H 2 cell responses on allergen or rhinovirus challenge. Although it is not clear how exactly pDCs mediate T-cell activation, 2 possibilities are most likely. First, pDCs can act as classical antigen-presenting cells to boost effector T H 2 cell responses and T H 2-mediated inflammation. In support of this, pDCs upregulate CD40 and OX40L, 2 key costimulatory molecules involved in pDC activation and/or the ability to drive T H 2 cell differentiation. 19, 45 Alternatively, pDCs might not directly present antigen but support through their presence conventional dendritic cell-T-cell interactions or ILC2-mediated type 2 responses. However, against the latter possibility, TLR7/8-activated pDCs have been shown recently to inhibit ILC2 function through production of type I interferons. 46 Type I interferons are broadly suppressive of type 2 immunity and therefore are not likely to account for pDC-induced disease exacerbations in this context. 47 Further studies to dissect these various possibilities will be needed.
The fact that pDCs are activated during established disease and exacerbations might explain the apparent discrepancy between our work and previous studies on the role of pDCs in AAD in experimental animals. These have shown that depletion of pDCs before allergen challenge (ie, before the development of inflammation) aggravates disease, but pDCs in this context are not activated and thus have the propensity to promote tolerogenic and/or immunoregulatory effects. In contrast, in our model systems pDCs are examined when disease is established and cells are thus activated. In terms of therapy, studying the role of pDCs at the ''chronic'' phase of the disease is more relevant because patients who seek medical attention and are in need of treatment either to control persistent symptoms or exacerbations have already established asthma.
A question that arises is what controls the pDC activation state and ensures pDC migration to the MLNs to induce effector T H 2 responses. Although several factors have been proposed to enhance pDC activation and T H 1 cell priming capability, including CD40 ligand, TLR stimulation, and viral infection, 42, 48, 49 only IL-3 has been shown to effectively promote T H 2 development, at least in culture. 42, 43 Our study now points to an important role of IL-25 in this process. IL-25 is induced at high levels in response to allergen exposure or viral infection and acts directly on pDCs to condition them toward proinflammatory activation. This is not limited to mouse cells because IL-25 acts in synergy with TLR9 to activate human pDCs as well. 28 Accordingly, exogenous IL-25 administration triggers pDC migration to the lungs and MLNs in experimental animals and exacerbates AAD, whereas endogenous IL-25 neutralization exerts the opposite effects. Although these findings do not establish unequivocally the causal effect of IL-25 in these processes, because pDC-independent effects of IL-25 can also be important, they suggest that IL-25 is a key moderator of the proinflammatory ''switch'' of pDCs and their migration to the MLNs. They also underscore the importance of the airway epithelium in the ''education'' of pDC function in the respiratory mucosa.
Previous studies have pointed to a potential role of lung pDCs in human asthma. They have shown that pDCs are present in the sputum and BAL fluid of patients with stable asthma and that their numbers can be increased further on allergen provocation. [26] [27] [28] Our study now greatly expands this earlier work by revealing the major role of pDCs in asthma exacerbations and shedding light on their functional importance.
The observation that pDCs are linked to higher inflammatory burden in the lung during acute exacerbations and the fact that pDC depletion abrogates exacerbations in experimental animal models provides the rationale for interfering with pDC function for therapy. Moreover, the demonstration that pDC numbers are increased in the same patient during an exacerbation and that higher pDC numbers are present in patients with stable asthma with frequent exacerbations supports the tracking of sputum pDC levels for diagnostic and prognostic purposes.
Interestingly, previous studies have also indicated opposing roles of pDCs in the respiratory tract. In the nasal mucosa of patients with chronic rhinosinusitis, pDCs have been shown to be activated and capable of promoting T H 1 and/or T H 2 cell differentiation, depending on the disease phenotype. 50 In contrast, in human tonsils of allergic patients, pDCs have been demonstrated to prevent allergic responses by inducing allergen-specific forkhead box protein 3-positive regulatory T-cell responses. 51, 52 Therefore the ability of pDCs to induce T H 2 versus T H 1 or regulatory T-cell responses in the respiratory track appears to be context specific and amenable to inflammatory, environmental, and tissue-intrinsic cues and should be taken into account when therapeutic applications are considered.
In summary, our study reveals a new role of pDCs in patients with AAD and supports the targeting of pDCs or their upstream activator, IL-25, for the treatment of difficult-to-control asthma, especially asthma exacerbations. It also advocates for monitoring pDCs in patients' sputum as a potential novel way for diagnosing the severity of asthma and predicting the risk of exacerbations and therefore has the potential to significantly impact human health.
METHODS

Mice and viruses
C57BL/6 wild-type and BALB/c mice were purchased from Jackson Laboratory (Bar Harbor, Me). All mice were housed in individually ventilated cages under specific pathogen-free conditions at the Animal House Facility of the Foundation for Biomedical Research of the Academy of Athens (Athens, Greece) in full compliance with the Federation of European Laboratory Animal Science Association recommendations. Rhinovirus 1B (American Type Culture Collection) was grown, purified, and titrated in HeLa cells (European Collection of Cell Cultures) by using standard methods, as previously described.
E1 All animal studies were approved by the Biomedical Research Foundation, Academy of Athens Ethics Review Board, and local authorities and were in accordance with national and European legislation and guidelines.
Mouse models and treatments
Allergic airway inflammation was induced in 8-to 12-week-old C57BL/6 mice. Mice were sensitized with 2 weekly intraperitoneal injections of 7.5 mg of OVA (Grade V; Sigma, St Louis, Mo) complexed with aluminum hydroxide (Sigma) and exposed subsequently to 3 daily aerosol challenges with 5% wt/vol OVA in PBS for 30 min/d, as previously described. E2 Control mice received intraperitoneal injections of OVA and challenges with PBS alone. In some cases mice were challenged with FITC-labeled OVA (Thermo Fischer Scientific, Waltham, Mass), as indicated. Rhinovirus exacerbation of allergic airway inflammation was induced in 8-to 12-week-old BALB/c mice sensitized and challenged with OVA as before. Immediately after the last OVA challenge, mice were exposed intranasally to 1 3 10 7 median tissue culture infective dose of rhinovirus 1B or saline, as previously reported. E1 For pDC depletion, mice were treated intraperitoneally with 250 mg per mouse of 120G8 anti-mouse antibody (Dendritics), rat IgG 2a (clone 2A3), or IgG 1 anti-b-GAL (Bio X Cell) or vehicle (PBS), as indicated in the experimental protocol. For IL-25 treatment, mice were administered intranasally 1 mg per mouse of rIL-25 (BioLegend) or PBS as specified. For IL-25 neutralization, mice were treated intraperitoneally with 500 mg per mouse of anti-mouse IL-25 (clone DDG91; Janssen Pharmaceuticals) or anti-b-Gal rat IgG 1 isotype control. Mice were killed at various time points for end point analyses, including inflammatory cell infiltration in the BAL fluid and tissues, histopathologic analysis, airway hyperreactivity, and OVA-specific MLN responses.
Flow cytometric analysis of mouse lung and MLN suspensions
Total pulmonary leukocytes were recovered by cutting lungs into small pieces and digesting them in complete medium with collagenase IV (Sigma C5138) for 60 minutes at 378C. Single-cell suspensions from lungs and MLNs were then obtained by means of homogenization and filtered through a 40-mm nylon filter. Cell viability determined by using Trypan blue exclusion was greater than 95%. Cells were stained with cell type-specific antibodies (BioLegend), and numbers of pDCs (CD45 BAL and differential cell counts BAL fluid was obtained by lavaging the airways of mice 2 times with 0.5 mL of PBS through a tracheal cannula. Cells were counted and pelleted onto glass slides, and differential cell counts for eosinophils, lymphocytes, neutrophils, and monocytes/macrophages were performed on MayGr€ unwald-stained cytospin preparations.
MLN responses
Single-cell suspensions from MLNs were prepared, and cells were cultured at 5 3 10 5 cells/well in 96-well plates in the presence or absence of OVA (100 mg/mL). Supernatants were collected at 48 hours and examined by means of ELISA for the presence of cytokines.
Ex vivo removal of pDCs from MLN cultures
Flow cytometric cell sorting of total versus CD45 
Bone marrow-derived pDCs
Bone marrow cells were cultured with 200 ng of Flt3 (Amgen, Thousand Oaks, Calif) for 7 days, harvested, and cell sorted for CD11c 1 B220 1 pDCs.
Sorted pDCs were plated in 96-well plates at a concentration of 2 3 10 5 cells/well, treated overnight with 25 ng/mL rIL-25 (BioLegend), and stimulated for 6 hours with 5 mmol/L ODN-1585 (InvivoGen, San Diego, Calif) or 10 mg/mL R-848 (InvivoGen). RNA was extracted and analyzed by using quantitative PCR (LightCycler 96; Roche, Mannheim, Germany) for the indicated genes.
Cytokine and chemokine measurements
Mouse cytokines were analyzed in MLN culture supernatants or BAL fluid by using ELISA or Luminex (Austin, Tex). ELISA kits were used for mouse IL-4, IL-5, IL-10, IL-13, IL-17A, and IL-25 (eBioscience, San Diego, Calif), IFN-a (eBioscience), IFN-b (BioLegend), and IFN-g (BioLegend). Luminex MILLIPLEX MAP kits (Millipore, Merck) were used for mouse IL-33 and TSLP. Luminex MILLIPLEX MAP kits (Millipore, Merck) were also used for all cytokine and chemokine measurements in sputum supernatants.
Measurement of airway hyperreactivity
Anesthetized mice were mechanically ventilated (flexiVent; SCIREQ, Montreal, Quebec, Canada), and aerosolized methacholine was delivered inline through the inhalation port for 10 seconds. Lung resistance was determined as the highest of 12 measurements obtained for each concentration of methacholine and is reported as the percentage increase from baseline.
E2
Histologic analysis, scoring, and morphometry Paraffin-embedded mouse lungs were stained with hematoxylin and eosin, and histopathologic analyses were performed blindly at the level of the bronchial tree of at least 6 mice per group. A semiquantitative scoring system assessing peribronchial and perivascular inflammation was used, providing a maximum score of 8, as previously described. E3 The histologic score for PBS/ PBS control mouse lungs was always 0.
Immunofluorescence
Lung tissues were inflated in 4% PFA:OCT (2:1), embedded in OCT, and cut into 5-mm-thick sections. Sections were mounted on adhesive-coated slides and fixed with acetone. For antigen retrieval, tissues were incubated in sodium citrate buffer (10 mmol/L sodium citrate and 0.05% Tween 20, pH 6.0) for 30 minutes at 808C, and endogenous peroxidase activity was blocked with 0.3% H 2 O 2 for 60 minutes. Sections were blocked for 60 minutes and incubated with rat anti-mouse 120G8 antibody (1:100, Dendritics) overnight. Sections were processed for endogenous biotin blocking (Biotin Avidin Kit Vector) and incubated with a biotin conjugated goat anti-rat antibody (Dako, Hamburg, Germany) for 60 minutes. Signal amplification was achieved by means of incubation with horseradish peroxidase-streptavidin and a tyramide reagent, as described by the manufacturer (TSA Kit T20934, Thermo Fisher Scientific). Nuclei were stained with 49-6-diamidino-2-phenylindole dihydrochloride. Sections were mounted with Prolong Diamond mounting medium (Thermo Fisher Scientific), placed under coverslips, and visualized with a Leica TCS-SP5II Confocal Microscope.
Sputum induction and processing
Sputum was induced by means of inhalation of hypertonic saline aerosol and processed by using standard methodologies. E4 Briefly, 15 minutes after salbutamol inhalation (200 mg), subjects were exposed to normal saline (0.9%) and then hypertonic saline (3%, 4%, and 5%) aerosolized through an ultrasonic nebulizer (ULTRA-NEB 2000; DeVilbiss Healthcare, Somerset, Pa) over a period of 7 minutes per concentration and then encouraged to cough deeply. All subjects produced an adequate amount of sputum, which was always processed within 1 hour of collection. Sputum plugs were separated from contaminating saliva, weighed, and diluted 3-fold with PBS containing 0.1% dithiothreitol (AppliChem, Darmstadt, Germany). After a 20-minute incubation, the supernatant was collected, and cells were washed and gravity filtered sequentially through 100-and 40-mm pore mesh filters. Cells were further cleared by means of 15%/20% Percoll density gradient centrifugation for cell counting and flow cytometry. Sputum leukocyte fractions were subjected to immediate flow cytometric analysis, whereas supernatants were kept at 2708C for subsequent measurements.
Flow cytometric analysis of sputum samples
Sputum leukocyte fractions were subjected to multicolor flow cytometry. All human antibodies were from BioLegend, with the exception of CD86, which was from BD PharMingen. pDCs were identified as CD45 C57BL/6 mice sensitized with OVA in alum and challenged with aerosolized OVA were analyzed at days 1, 4, 7, and 11 after challenge. Naive mice and OVA-sensitized saline-challenged mice were used as controls.
A-E, Total leukocyte (Fig E1, A) , eosinophil (Fig E1, B) , monocyte/macrophage (Fig E1, C) , neutrophil (Fig E1,  D) , and lymphocyte (Fig E1, E) Fig E2, B and C), 14 to 20 (Fig E2, D-F) , or 8 to 18 (Fig E2, G) mice per group from 1 to 3 independent experiments are shown. *P < .05, **P < .01, and ***P < .001. One representative from 3 independent experiments is shown. B, Schematic of the experimental setup of the ex vivo removal of pDCs using flow cytometry. MLN cells were sorted by using flow cytometry into 2 populations: MLN cells without pDCs and highly purified pDCs. These were repooled together or kept independently and stimulated with OVA, and supernatants were analyzed at 48 hours. FS, Forward scatter; SS, side scatter. C, Schematic of the experimental setup of the ex vivo removal of pDCs using anti-PDCA-1 staining and magnetic beads. D, Cytokine production of IL-5, IL-10, and IL-13 in supernatants of medium-or OVA-stimulated MLNs before or after pDC depletion expressed as means 6 SEMs from 6 to 9 mice per group. Data of 2 independent experiments are shown. *P < .05 and ***P < .001. 
